GenSight Biologics S.A. SIGHT.PA Stock
GenSight Biologics S.A. Price Chart
GenSight Biologics S.A. SIGHT.PA Financial and Trading Overview
| GenSight Biologics S.A. stock price | 0.4 EUR |
| Previous Close | 0.77 EUR |
| Open | 0.78 EUR |
| Bid | 0 EUR x 0 |
| Ask | 0 EUR x 0 |
| Day's Range | 0.77 - 0.78 EUR |
| 52 Week Range | 0.48 - 4.59 EUR |
| Volume | 22.53K EUR |
| Avg. Volume | 425.46K EUR |
| Market Cap | 37.89M EUR |
| Beta (5Y Monthly) | 1.929885 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.63 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.2 EUR |
SIGHT.PA Valuation Measures
| Enterprise Value | 41.06M EUR |
| Trailing P/E | N/A |
| Forward P/E | -1.1057143 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.7892876 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 8.439 |
| Enterprise Value/EBITDA | -1.492 |
Trading Information
GenSight Biologics S.A. Stock Price History
| Beta (5Y Monthly) | 1.929885 |
| 52-Week Change | -65.50% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.59 EUR |
| 52 Week Low | 0.48 EUR |
| 50-Day Moving Average | 1.18 EUR |
| 200-Day Moving Average | 2.8 EUR |
SIGHT.PA Share Statistics
| Avg. Volume (3 month) | 425.46K EUR |
| Avg. Daily Volume (10-Days) | 111.68K EUR |
| Shares Outstanding | 46.18M |
| Float | 31.03M |
| Short Ratio | N/A |
| % Held by Insiders | 12.75% |
| % Held by Institutions | 35.49% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -572.14% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -42.12% |
| Return on Equity (ttm) | -7781.69% |
Income Statement
| Revenue (ttm) | 4.87M EUR |
| Revenue Per Share (ttm) | 0.11 EUR |
| Quarterly Revenue Growth (yoy) | -25.80% |
| Gross Profit (ttm) | 4.87M EUR |
| EBITDA | -27525000 EUR |
| Net Income Avi to Common (ttm) | -27625000 EUR |
| Diluted EPS (ttm) | -0.59 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 10.61M EUR |
| Total Cash Per Share (mrq) | 0.23 EUR |
| Total Debt (mrq) | 17.86M EUR |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 1.567 |
| Book Value Per Share (mrq) | -0.331 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -33753000 EUR |
| Levered Free Cash Flow (ttm) | -29489124 EUR |
Profile of GenSight Biologics S.A.
| Country | France |
| State | N/A |
| City | Paris |
| Address | 74, rue du Faubourg Saint-Antoine |
| ZIP | 75012 |
| Phone | 33 1 76 21 72 20 |
| Website | https://www.gensight-biologics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 45 |
GenSight Biologics S.A., a clinical-stage biotechnology company, discovers, develops, and commercializes therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company is also developing products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. The company was incorporated in 2012 and is headquartered in Paris, France.
Q&A For GenSight Biologics S.A. Stock
What is a current SIGHT.PA stock price?
GenSight Biologics S.A. SIGHT.PA stock price today per share is 0.4 EUR.
How to purchase GenSight Biologics S.A. stock?
You can buy SIGHT.PA shares on the Paris exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for GenSight Biologics S.A.?
The stock symbol or ticker of GenSight Biologics S.A. is SIGHT.PA.
Which industry does the GenSight Biologics S.A. company belong to?
The GenSight Biologics S.A. industry is Biotechnology.
How many shares does GenSight Biologics S.A. have in circulation?
The max supply of GenSight Biologics S.A. shares is 78.03M.
What is GenSight Biologics S.A. Price to Earnings Ratio (PE Ratio)?
GenSight Biologics S.A. PE Ratio is now.
What was GenSight Biologics S.A. earnings per share over the trailing 12 months (TTM)?
GenSight Biologics S.A. EPS is -0.63 EUR over the trailing 12 months.
Which sector does the GenSight Biologics S.A. company belong to?
The GenSight Biologics S.A. sector is Healthcare.
GenSight Biologics S.A. SIGHT.PA included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| CAC Small CS90 | 11739.13 EUR 12832.46 USD |
-0.74
|
— — | — — | — — | — - | — — |
| CAC Mid & Small MS190 | 14267.59 EUR 15596.4 USD |
-0.38
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}